# SENTI-202 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/senti-202

> SENTI-202, sponsored by Senti Biosciences Holdings, Inc. (SNTI): 9 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | SENTI-202 |
| Codes | SENTI-202 |
| Sponsor | Senti Biosciences Holdings, Inc. (SNTI) https://sec-api.dev/companies/snti/catalysts |
| Indications | [hematologic malignancies](https://sec-api.dev/indications/hematologic-malignancies), [relapsed/refractory hematologic malignancies](https://sec-api.dev/indications/relapsed-refractory-hematologic-malignancies), relapsed/refractory |
| Modality |  |
| FDA designations | orphan, rmat |

## Timeline

### Dec 2023: trial start

- Status: completed. Date confidence: month. Stage: 1. Indication: hematologic malignancies.
- First seen 2024-11-14, last confirmed 2026-03-27.
- SEC Form 10-K (accession 0001628280-26-021580): "In December 2023, our IND application for evaluation of SENTI-202 in patients with hematologic malignancies was cleared by the FDA, and we began dosing patients in an open-label Phase 1 clinical trial in the United States and Australia in the second quarter of 2024." https://www.sec.gov/Archives/edgar/data/1854270/000162828026021580/snti-20251231.htm
- SEC Form 10-K (accession 0001854270-25-000042): "In December 2023, our IND application for evaluation of SENTI-202 in patients with hematologic malignancies was cleared by the FDA, and we began dosing patients in an open-label Phase 1 clinical trial in the United States and Australia in the second quarter of 2024." https://www.sec.gov/Archives/edgar/data/1854270/000185427025000042/snti-20241231.htm
- SEC Form 10-Q (accession 0001854270-24-000116): "•We received clearance of our IND for our first product candidate, SENTI-202, in December 2023, and announced our first patient dosed in the Phase 1 clinical trial of SENTI-202 in May 2024." https://www.sec.gov/Archives/edgar/data/1854270/000185427024000116/snti-20240930.htm

### late 2024: interim data readout

- Status: scheduled. Date confidence: half.
- First seen 2024-11-14, last confirmed 2024-11-14.
- Press release filed with the SEC (EX-99) (accession 0001854270-24-000114): "Initial safety and efficacy data readout remains on-track by year-end 2024 and initial durability data is expected to follow in 2025." https://www.sec.gov/Archives/edgar/data/1854270/000185427024000114/a20241114ex991earningsrele.htm

### November 14, 2024: trial start

- Status: completed. Date confidence: exact. Stage: 1. Indication: relapsed/refractory hematologic malignancies.
- First seen 2024-11-14, last confirmed 2024-11-14.
- Press release filed with the SEC (EX-99) (accession 0001854270-24-000114): "SENTI-202 for Acute Myeloid Leukemia ("AML"): The Company announced that patient dosing has commenced, and is ongoing, in the Phase 1 clinical trial of SENTI-202 (NCT06325748) for the treatment of relapsed/refractory hematologic malignancies including AML." https://www.sec.gov/Archives/edgar/data/1854270/000185427024000114/a20241114ex991earningsrele.htm

### December 2, 2024: interim data readout

- Status: completed, positive. Date confidence: exact. Stage: 1. Indication: relapsed/refractory hematologic malignancies.
- First seen 2024-11-14, last confirmed 2024-12-02.
- Press release filed with the SEC (EX-99) (accession 0001140361-24-048114): "SOUTH SAN FRANCISCO, Calif., December 2, 2024 - Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported positive initial clinical data from a Phase 1 clinical trial of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer ("CAR-NK") investigational cell therapy, for the treatment of relapsed/refractory ("R/R") hematologic malignancies including acute myeloid leukemia ("AML")." https://www.sec.gov/Archives/edgar/data/1854270/000114036124048114/ef20039399_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001854270-24-000114): "- Enrollment continues in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML; initial clinical data expected in Q4 2024 -" https://www.sec.gov/Archives/edgar/data/1854270/000185427024000114/a20241114ex991earningsrele.htm

### May 6, 2025: earnings report

- Status: completed. Date confidence: exact.
- First seen 2025-05-06, last confirmed 2025-05-06.
- Press release filed with the SEC (EX-99) (accession 0001854270-25-000062): "Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development" https://www.sec.gov/Archives/edgar/data/1854270/000185427025000062/ex991snti2025q125earningsr.htm

### August 7, 2025: earnings report

- Status: completed. Date confidence: exact.
- First seen 2025-08-07, last confirmed 2025-08-07.
- Press release filed with the SEC (EX-99) (accession 0001854270-25-000088): "Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025" https://www.sec.gov/Archives/edgar/data/1854270/000185427025000088/ex991snti2025q125earningsr.htm

### late 2025: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-11-13, last confirmed 2025-11-13.
- SEC Form 10-Q (accession 0001628280-25-052125): "Enrollment is ongoing in the expansion cohort at the RP2D, with topline data expected before the end of 2025." https://www.sec.gov/Archives/edgar/data/1854270/000162828025052125/snti-20250930.htm

### November 13, 2025: earnings report

- Status: completed. Date confidence: exact.
- First seen 2025-11-13, last confirmed 2025-11-13.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-052083): "Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December" https://www.sec.gov/Archives/edgar/data/1854270/000162828025052083/ex991snti2025q325earningsr.htm

### May 14, 2026: earnings report

- Status: completed. Date confidence: exact.
- First seen 2026-05-14, last confirmed 2026-05-14.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-034834): "Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase" https://www.sec.gov/Archives/edgar/data/1854270/000162828026034834/ex991sntiq126earningsrelea.htm

## Same indication

- [GTB-3650](https://sec-api.dev/pdufa/gtb-3650) (GTBP)
- [KOMET-001](https://sec-api.dev/pdufa/komet-001) (KURA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/senti-202.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SENTI-202 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/senti-202

```bibtex
@misc{secapidev_pdufa_senti_202_20261116,
  title        = {SENTI-202 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/senti-202}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_senti_202_20261116","title":"SENTI-202 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/senti-202","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
